Bernstein reiterates Revvity stock rating ahead of investor day
Bernstein reiterated a Market Perform rating on Revvity (NYSE:RVTY) with a $160 price target ahead of its investor day. The stock trades at $158.25, but is considered overvalued. Bernstein expects AI in drug discovery to be the focus. Revvity reported Q3 2026 earnings of $1.37 per share on $729M revenue, beating estimates. BofA and Stifel raised their price targets to $185 and $177, respectively, citing strong performance and AI demand.
How this was made
The 30-second read
Why it matters
The reiteration offers little new information, keeping the stock near its current level. Investors may watch the upcoming investor day for fresh catalysts.
Market read
Low immediate trading relevance; the rating repeat is a minor data point ahead of an investor day.
What to watch
Potential surprise announcements at the investor day could change the outlook, but are not disclosed yet.
Background
Bernstein and SocGen reaffirmed a Market Perform rating for Revvity (RVTY) with a $160 target ahead of its investor day. The firm highlighted AI in drug discovery as a key theme. The article also recapped Q3 2026 results that were released earlier.
Ticker impact
Bernstein reiterated a Market Perform rating with a $160 price target ahead of Revvity's investor day.
likely slight downside as the rating offers no new upside catalyst
Analyst reiteration without new upgrade or downgrade provides limited actionable insight.
Market effects
AI focus may keep Revvity in view for life‑science AI investors, but no immediate sector shift.
U.S. biotech sector sees modest attention; no broader market effect.
Limited to investors tracking Revvity and AI in drug discovery.
Counterpoint
The rating reiteration could be a sign of caution; investors might wait for post‑investor‑day data before acting.
Key entities
- AnalystBernstein
Equity research firm providing the rating.
- CompanyRevvity Inc
Life‑science tools maker focusing on AI-driven drug discovery.
